Evaluation of the In Vitro Cytotoxic Activity of Jania rubens Against Jurkat and Molt-4 Human Cancer Cell Lines

Unissa, Rahamat; Cheruvu, Sai; Tejaswi, Mulakalapalli; Raghavi, Mareda; Bindu, Nayakanti; Thota, Nishita; Bhavana, Pyata

doi:10.26538/tjnpr/v1i5.5

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the brown seaweed sterol hydrocarbon fraction showed dose-dependent anticancer efficacy against a number of cancer cell lines, including the Hep-G2 liver cancer cell line, the MCF-7 breast cancer cell line, the A549 colon cancer cell line, and the A549 ovarian cancer cell line [ 17 ]. Jania rubens (Rhodophyta) methanolic extracts demonstrated anticancer activity against the Molt-4 and Jurkat cell lines (IC 50 values of 60.25 and 62.5 g/mL, respectively), indicating that it could be a good source of anti-leukemia medicines [ 18 ]. By blocking vascular endothelial growth factor (VEGF) and natural killer (NK) cell activation, antitumor chemicals from seaweeds can cause cancer cell death via a variety of signaling pathways, including cell cycle arrest, apoptosis, and anti-angiogenesis [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Antitumor immunity and therapeutic properties of marine seaweeds-derived extracts in the treatment of cancer

et al. 2022

View full text Add to dashboard Cite

Marine seaweeds are important sources of drugs with several pharmacological characteristics. The present study aims to evaluate the antitumor and antitumor immunological potentials of the extracts from the brown alga Padinapavonica and the red alga Janiarubens, inhibiting the Egyptian marine coasts. Hep-G2 cell lines were used for assessment of the antitumor efficacy of Padinapavonica and Janiarubens extracts in vitro, while Ehrlich ascites carcinoma (EAC) cells were applied to gain more antitumor immunity and antitumor insights of P.pavonica and J.rubens extracts in vivo. In vitro antitumor potentials of P.pavonica and J.rubens extracts were analyzed against human liver cancer Hep-G2 cells by MTT and trypan blue exclusion assays. In vivo antitumor immunological potentials of P.pavonica and J.rubens extracts at low, high, and prophylactic doses were analyzed by blood counting and flow cytometry in mice challenged with Ehrlich ascites carcinoma (EAC) cells. In vitro results revealed that P.pavonica and J.rubens extracts caused significant decreases in the number and viability of Hep-G2 cells in a dose-dependent manner as compared to untreated Hep-G2 cells or Cisplatin®-treated Hep-G2 cells. In vivo findings showed that P.pavonica and J.rubens extracts at low, high, and prophylactic doses significantly reduced the number and viability of EAC tumor cells accompanied by increases in EAC apoptosis compared to naïve EAC mouse. Additionally, P.pavonica and J.rubens extracts at low and prophylactic doses remarkably increased both the total WBC count and the relative numbers of lymphocytes and decreased the relative numbers of neutrophils and monocytes. Flow cytometric analysis showed that P.pavonica and J.rubens extracts at the treatment and the prophylactic doses resulted in a significant increase in the phenotypic expressions of CD4+ T, CD8+ T, and CD335 cells compared to naïve EAC mouse. Overall, both extracts P.pavonica and J.rubens possess potential antitumor and antitumor immunological effects with less toxicity, opening new approaches for further studies of the chemical and biological mechanisms behind these effects.

show abstract

Section: Introductionmentioning

confidence: 99%